All issues
Volume 46, Issue 4
Displaying 1-10 of 10 articles from this issue
- |<
- <
- 1
- >
- >|
-
[in Japanese]2005 Volume 46 Issue 4 Pages 233-239
Published: 2005
Released on J-STAGE: July 28, 2009
JOURNAL RESTRICTED ACCESSDownload PDF (709K) -
[in Japanese]2005 Volume 46 Issue 4 Pages 240-244
Published: 2005
Released on J-STAGE: July 28, 2009
JOURNAL RESTRICTED ACCESSDownload PDF (482K) -
[in Japanese]2005 Volume 46 Issue 4 Pages 245-253
Published: 2005
Released on J-STAGE: July 28, 2009
JOURNAL RESTRICTED ACCESSDownload PDF (644K)
-
Shigeru HAYASHI, Akira WAKIZAKA2005 Volume 46 Issue 4 Pages 254-260
Published: 2005
Released on J-STAGE: July 28, 2009
JOURNAL RESTRICTED ACCESSWe encountered lower gastrointestinal bleeding in 16 patients taking a low dose of aspirin and examined the effect of low aspirin dose on the stool occult blood test in 49 thrombotic patients (mean: 76.7±9.6 years old) including 39 with cerebral infarction, 8 with ischemic heart disease and 2 with atrial fibrillation. The mean aspirin dosage was 81 mg/day over a period of 6-288 weeks (mean: 86.4±66.9 weeks). Positive occult blood test was seen in 16/49 (32.7%). Severe lower gastrointestinal bleeding was observed in one case (2%) with colon diverticulosis. Aspirin dosage per patient was significantly higher (p<0.01) in the occult blood test positive group (60.1±47.2 g) than in the occult blood test negative group (42.6±32.8 g). The positive ratio of occult blood test was significantly higher (p<0.01) in the aspirin and antithrombotic drugs-taking group (8/5; positive/negative) than in the aspirin-taking group (8/28; p/n), whereas it was not significant between the aspirin taking-group and aspirin not taking-group. The odds ratio between aspirin and antithrombotic drugs (warfarin, beraprost, cilostazol or ticlopidine)-taking group and the aspirin-taking group was 3.47 (p<0.05). A low dose of aspirin was associated with a positive occult blood test. Aspirin should be carefully administered when patient has a diverticle or is taking other antithrombotic drugs.View full abstractDownload PDF (791K) -
Seiko IKI, Kensuke USUKI, Kimiko IIJIMA, Akio URABE2005 Volume 46 Issue 4 Pages 261-268
Published: 2005
Released on J-STAGE: July 28, 2009
JOURNAL RESTRICTED ACCESSWe evaluated the efficacy and long-term outcomes of immunosuppressive therapy (IST) in 50 adult patients with aplastic anemia at a single institution. Twenty-one patients who had not responded to the first course of IST or relapsed after the initial response to IST were retreated with the second course of IST with antithymocyte globulin. The response and relapse rate of the initial IST were 76.7% and 23.3%, respectively. The response rate of salvage IST was 61.9%. Overall survival at 10 years was 84.0%. Failure-free survival at 10 years was 62.0%. Clonal or malignant diseases developed in 2 patients. Early deaths due to bleeding or infection were observed only in elderly patients. We conclude that most patients with aplastic anemia treated with IST show hematologic improvement and excellent long-term survival.View full abstractDownload PDF (948K)
-
Hiroshi IKEDA, Toshiaki HAYASHI, Masahiro NOJIMA, Hiroshi YASUI, Yukih ...2005 Volume 46 Issue 4 Pages 269-273
Published: 2005
Released on J-STAGE: July 28, 2009
JOURNAL RESTRICTED ACCESSWe describe 2 cases of conventional therapy-resistant multiple myeloma (MM) that responded to bortezomib and dexamethasone therapy. Case 1: A 62-year-old woman with MM (IgG, κ-type, stage IIIA) resistant to DMVM-IFN (dexamethasone, ranimustine, vincristine, melphalan, interferon-α), VAD (vincristine, doxorubicin, dexamethasone), high-dose melphalan with autologous peripheral blood stem cell transplantation (PBSCT) and thalidomide, received 2 courses of bortezomib treatment. In the first course, bortezomib alone was administered and then in the second course bortezomib was given in combination with dexamethasone. The patient's serum IgG level decreased from 8040 to 1020 mg/dl and the level of plasma cells in bone marrow was 1.2% after the treatments. Adverse reactions including rash, anemia, and thrombocytopenia occurred in the first course; however, they were milder in the second course combined with dexamethasone. Case 2: A 43-year-old man with MM (IgD, λ-type, stage IIA) resistant to conventional and high-dose chemotherapy with PBSCT as well as thalidomide therapy, received treatment with bortezomib alone and then in combination with dexamethasone. His serum IgD level decreased from 2140 to 623 mg/dl. He suffered adverse reactions such as fatigue, anemia, and thrombocytopenia in the first course, which were relieved in the second course. These results indicate that the combination of bortezomib and dexamethasone is effective in the treatment of refractory MM and that dexamethasone can reduce the adverse reactions of bortezomib.View full abstractDownload PDF (897K) -
Hidemitsu KUROSAWA, Tatsuo TSUBOI, Hagane SHIMAOKA, Mayuko OKUYA, Dais ...2005 Volume 46 Issue 4 Pages 274-277
Published: 2005
Released on J-STAGE: July 28, 2009
JOURNAL RESTRICTED ACCESSA 4-year-old boy with Down syndrome (DS) was diagnosed as having acute monoblastic leukemia (AML-M5a). Leukemic cells were CD33+, CD56+ and CD4+, with t(9;11) on cytogenetic analysis and MLL gene rearrangement. After 2 courses of induction therapy using an AML 99-Down protocol failed to obtain complete remission, the patient received cord blood transplantation from an HLA-matched donor (CBT) following a conditioning regimen comprising total body irradiation and cyclophosphamide. Only cyclosporin A was used for graft-versus-host disease prophylaxis. Stem cell transplantation may not be indicated for AML patient with DS in first remission, who display a high rate of life-threatening and fatal toxicity on therapy. This patient remained well controlled in complete remission for 4 years, representing a rare case of DS with chemotherapy-resistant AML successfully treated with a CBT.View full abstractDownload PDF (734K)
-
Asako KITANO, Koh YAMAMOTO, Toshikage NAGAO, Minako YOSHIDA, Tetsuya K ...2005 Volume 46 Issue 4 Pages 278-280
Published: 2005
Released on J-STAGE: July 28, 2009
JOURNAL RESTRICTED ACCESSA 53-year-old male was admitted because of pancytopenia and chronic subdural hematoma. Bone marrow was hypercellular with 97% blasts, which expressed CD10, CD19, CD20, and immunoglobulin μ and λ chains on the cell surface and had chromosomal abnormalities including t(8;22)(q24;q11). The patient was diagnosed as having Burkitt leukemia. Because hemiplegia and disturbance of consciousness developed rapidly, the patient was treated with an emergency drainage operation followed by Hyper-CVAD therapy and achieved a sustained complete remission. Dural infiltration of leukemic cells as well as thrombocytopenia was implicated in the pathogenesis of the subdural hematoma, which contained numerous blasts.View full abstractDownload PDF (527K) -
Hiroyuki KURODA, Masaya KIDA, Hideki WATANABE, Sayaka SHIRAO, kyuhei K ...2005 Volume 46 Issue 4 Pages 281-283
Published: 2005
Released on J-STAGE: July 28, 2009
JOURNAL RESTRICTED ACCESSWe encountered a case of follicular lymphoma in a patient with high levels of serum CA125. On examination, abdominal lymph node swelling and hepatosplenomegaly were observed. The CA125 level decreased during treatment and was normalized at complete remission. An immunohistochemical assay of the lymphoma cells, however, failed to demonstrate any CA125. Several reports have described that CA125 might be produced by mesothelial cells in response to cytokines released by the lymphoma cells, and increased levels of CA125 have been significantly associated with abdominal involvement. It is possible that CA125 will become a useful marker in the observation of the progression of malignant lymphoma in the abdomen.View full abstractDownload PDF (457K)
-
2005 Volume 46 Issue 4 Pages 284-295
Published: 2005
Released on J-STAGE: July 28, 2009
JOURNAL RESTRICTED ACCESSDownload PDF (853K)
- |<
- <
- 1
- >
- >|